Small Cell Lung Cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Small Cell Lung Cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Small Cell Lung Cancer: Overview
Small cell lung cancer accounts only for 13% of the lung cancers. However, SCLC is the more aggressive form of lung cancer. With SCLC, the cancer cells tend to grow quickly and travel to other parts of the body, or metastasize, more easily. Small cell lung cancer is more strongly linked to smoking. Small cell lung cancer typically have had relatively very few symptoms. The symptoms can result from local growth of the tumor, spread to nearby areas, distant spread, paraneoplastic syndromes, or a combination thereof. SCLC diagnosis begins with a thorough physical examination and medical history. When SCLC reaches the extensive stage, treatment is aimed at relieving symptoms, not at curing the disease.
'Small Cell Lung Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Small Cell Lung Cancer Emerging Drugs
Further product details are provided in the report……..
Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Small Cell Lung Cancer drugs.
Small Cell Lung Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Small Cell Lung Cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Small Cell Lung Cancer: Overview
Small cell lung cancer accounts only for 13% of the lung cancers. However, SCLC is the more aggressive form of lung cancer. With SCLC, the cancer cells tend to grow quickly and travel to other parts of the body, or metastasize, more easily. Small cell lung cancer is more strongly linked to smoking. Small cell lung cancer typically have had relatively very few symptoms. The symptoms can result from local growth of the tumor, spread to nearby areas, distant spread, paraneoplastic syndromes, or a combination thereof. SCLC diagnosis begins with a thorough physical examination and medical history. When SCLC reaches the extensive stage, treatment is aimed at relieving symptoms, not at curing the disease.
'Small Cell Lung Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Small Cell Lung Cancer.
This segment of the Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Small Cell Lung Cancer Emerging Drugs
- HLX-10: Henlix Biotech
- Tiragolumab: Genentech
- Tislelizumab: BeiGene
- Lucitanib: Haihe Bipharma
- LP002: Taizhou HoudeAoke Biomedical Co., Ltd.
- LY 01610: Luye Pharma Group, Ltd
Further product details are provided in the report……..
Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Small Cell Lung Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
- Product Type
Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Small Cell Lung Cancer drugs.
Small Cell Lung Cancer Report Insights
- Small Cell Lung Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Small Cell Lung Cancer drugs?
- How many Small Cell Lung Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Small Cell Lung Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Small Cell Lung Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Small Cell Lung Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Small Cell Lung Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
HLX-10: Henlix Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LP002: Taizhou HoudeAoke Biomedical Co., Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
APG-1252: Ascentage Pharma Group Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Small Cell Lung Cancer Key Companies
Small Cell Lung Cancer Key Products
Small Cell Lung Cancer- Unmet Needs
Small Cell Lung Cancer- Market Drivers and Barriers
Small Cell Lung Cancer- Future Perspectives and Conclusion
Small Cell Lung Cancer Analyst Views
Small Cell Lung Cancer Key Companies
Appendix
Executive Summary
Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Small Cell Lung Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
HLX-10: Henlix Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LP002: Taizhou HoudeAoke Biomedical Co., Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
APG-1252: Ascentage Pharma Group Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Small Cell Lung Cancer Key Companies
Small Cell Lung Cancer Key Products
Small Cell Lung Cancer- Unmet Needs
Small Cell Lung Cancer- Market Drivers and Barriers
Small Cell Lung Cancer- Future Perspectives and Conclusion
Small Cell Lung Cancer Analyst Views
Small Cell Lung Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
